Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer
This study is a single-center, randomized controlled, phase II clinical trial, aiming at giving a comparison of Sintilimab and Pembrolizumab in stage IIIB-IV NSCLC patients at first-line treatment setting.
Nsclc
DRUG: Sintilimab|DRUG: Pembrolizumab
Objective response rate (ORR), Defined as the percentage of patients whose tumors have a complete or partial response to treatment, Up to 3 years
This trial has been set up with two arms. Screened patients would be included into one of the arms based on tumor PD-L1 expression. The purpose of this study is to compare the efficacy of the approved checkpoint inhibitor pembrolizumab and home-made drug Sintilimab in patients with advanced NSCLC whose tumor have high PD-L1 expression and low or negative expression.